1. Lesion location is the strongest and most consistent predictor

This is the one factor that keeps showing up across studies and treatment types. Lesions on the face and neck usually respond best. The trunk often does reasonably well. Hands, feet, fingertips, and other acral areas are usually the hardest places to repigment.

This pattern appears in phototherapy data, guideline-based summaries, and newer analyses of topical ruxolitinib. So yes, location matters. The skin is not a democracy.

2. Stable disease usually responds better than active disease

If vitiligo is still spreading, treatment may first need to calm disease activity before visible repigmentation becomes realistic. Clinical signs such as Koebnerization, confetti-like lesions, mucosal involvement, and other markers of activity are generally linked to a worse prognosis and often a weaker repigmentation response.

By contrast, stable localized disease tends to have better odds overall and is also the setting where surgical approaches perform best.

3. Perifollicular pigmentation is a good sign

When dermoscopy shows pigment preserved around hair follicles, that usually means there is still a melanocyte reservoir that treatment can recruit. In a prospective NB-UVB study, face location and baseline perifollicular pigmentation were associated with better clinical improvement.

4. Leukotrichia usually predicts a weaker response to standard medical treatment

White hairs inside a vitiligo lesion often mean that the follicular reservoir is reduced or exhausted. That is why leukotrichia is commonly associated with poorer response to conventional treatment, especially phototherapy and topical treatment alone.

Important nuance: poorer response does not mean no response. It just means expectations should be more realistic, and in selected stable cases, surgical options may become more relevant.

5. Early visible improvement is a practical real-world clue

Early repigmentation after treatment starts is usually a good sign. The recent narrative review on topical ruxolitinib found that early clinical improvement was associated with better longer-term outcomes. In practice, this makes sense: if a patch begins to wake up early, it often keeps going.

6. Time on treatment matters more than many people would like

Vitiligo treatment is usually slow. For phototherapy, the literature suggests that at least six months may be needed before judging whether a patient is truly responding. Stopping too early is common. Also understandable. Also not always wise.

7. Biomarkers may matter in the future, but they are not ready for prime time

There is growing interest in laboratory predictors such as cytokine patterns and CXCL10 changes. Some early data suggest these may be linked to treatment response, including with ruxolitinib. But at this point they remain exploratory and are not yet standard tools for everyday decision-making.

What is less reliable as a predictor?

Age, sex, skin phototype, and disease duration show mixed and inconsistent results across studies. Some papers suggest they matter in certain settings. Others do not. So these are weaker guides than location, stability, perifollicular pigmentation, leukotrichia, and early response.

Bottom line

The best responders are often stable lesions on the face or neck, without leukotrichia, with visible perifollicular pigmentation, and with early signs of repigmentation after treatment begins.

The toughest lesions are usually active or spreading patches on acral areas such as the hands and feet, especially when white hairs are already present.

That said, these are predictors, not verdicts. They improve expectation-setting. They do not replace individualized treatment planning.